Nicole Josephsen
Payments from drug & device makers
Across 68 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$566
- AbbVie$84
- Pfizer$63
- Novartis$59
- Mylan Specialty L.p.$57
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$40
- plus $326 from 15 others
What the payments were for
- Food & beverage$1,177100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $566 |
| AbbVie | 5 | $84 |
| Pfizer | 4 | $63 |
| Novartis | 3 | $59 |
| Mylan Specialty L.p. | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Seqirus USA Inc | 2 | $36 |
| Viatris Specialty LLC | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $31 |
| Merck | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Amgen | 2 | $27 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| GSK | 1 | $13 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$116
How this compares
$1,195 in reported general payments places this provider in the 75th percentile of 809 family providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $64,110 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $55,082 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $48,012 |
| MounjaroTirzepatide | 23 | $25,249 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $12,346 |
| FarxigaDapagliflozin Propanediol | 12 | $7,373 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $7,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $566 | $64,11053 claims |
| Lilly USA, LLCMounjaro | $15 | $25,24923 claims |
| AstraZenecaFarxiga | $13 | $7,37312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 809 family providers in Nebraska.
Other family in Wahoo
- Patricia TeeterWahoo$13K
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Mary MetzLincoln$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.